araag2/HINT huggingface dataset:
Clinical trial NCT00028002 (phase 2, status: completed)
Conditions: gastrointestinal stromal tumor
ICD codes: C49.A0, C49.A1, C49.A2, C49.A5, C49.A3, C49.A4, C49.A9
Drugs: imatinib mesylate
SMILES: CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed malignant gastrointestinal stromal tumor

               -  Potentially resectable primary disease

               -  Potentially resectable recurrent disease

                    -  Local or intra-abdominal/pelvic metastatic disease

          -  Documented c-kit (CD117) expression by immunohistochemical analysis of either initial
             core specimen or, if recurrent disease, from original tumor block

          -  Primary disease must be visceral, intra-abdominal, or pelvic in origin

          -  At least 1 unidimensionally measurable lesion

               -  At least 5 cm for primary disease

               -  At least 2 cm for recurrent disease

          -  At least 1 viable core biopsy tumor specimen obtained within 8 weeks before
             registration

          -  Performance status - Zubrod 0-2

          -  WBC at least 3,000/mm^3

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)

          -  ALT/AST no greater than 2.5 times ULN

          -  No uncontrolled chronic liver disease

          -  Creatinine no greater than 1.5 times ULN

          -  No uncontrolled chronic renal disease

          -  No New York Heart Association class III or IV cardiac disease

          -  Must be able to lie still in the PET scanner for approximately 1-2 hours

          -  No uncontrollable hyperglycemia

          -  No medical or psychological condition that would preclude study participation

          -  No severe or uncontrolled medical disease

          -  No active uncontrolled infection

          -  No known or suspected hypersensitivity to any component of the study drug

          -  Any prior malignancy is allowed provided patient remains disease free from that
             malignancy

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective barrier contraception during and for 3 months
             after study participation

          -  At least 28 days since prior biologic therapy

          -  No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF)

          -  At least 28 days since prior chemotherapy

          -  At least 28 days since prior radiotherapy

          -  See Disease Characteristics

          -  At least 28 days since prior investigational drugs

          -  At least 28 days since prior imatinib mesylate

          -  No concurrent therapeutic doses of warfarin

          -  Concurrent low-molecular weight heparin or mini-dose warfarin (1 mg per day)
             prophylaxis is allowed
Clinical trial NCT00690118 (phase 2, status: terminated)
Conditions: amyotrophic lateral sclerosis
ICD codes: G12.21
Drugs: pioglitazone, placebo
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    the interim analysis showed no tendency in favour of the verum group. therefore it was decided
    to stop the study prematurely.
  
Eligibility criteria:

        Inclusion Criteria:

          -  possible, probable (clinically or laboratory) or definite ALS according to the revised
             version of the El Escorial World Federation of Neurology criteria

          -  disease duration more than 6 months and less than 3 years

          -  best-sitting FVC between 50% and 95% of predicted normal

          -  continuously treated with 100 mg riluzole daily, for at least one month

          -  onset of progression weakness within 36 months prior to study

          -  women of childbearing age be non-lactating and surgically sterile or using a highly
             effective method of birth control and have a negative pregnancy test

          -  capable of thoroughly understanding all information given and giving full informed
             consent according to GCP

        Exclusion Criteria:

          -  previous participation in another clinical study within the preceding three months

          -  tracheotomy or assisted ventilation of any type during the preceding three months

          -  gastrostomy

          -  any medical condition known to have an association with motor neuron dysfunction which
             might confound or obscure the diagnosis of ALS

          -  presence of any concomitant life-threatening disease or impairment likely to interfere
             with functional assessment

          -  confirmed hepatic insufficiency or abnormal liver function (ASAT and/or ALAT more than
             1.5 upper limit of normal)

          -  renal insufficiency (serum creatinine more than 2.26 mg/dl)

          -  evidence of major psychiatric disorder or clinically evident dementia precluding
             evaluation of symptoms

          -  known hypersensitivity to any component of the study drugs

          -  likely to be not cooperative or comply with the trial requirements (as assessed by the
             investigator), or unable to be reached in the case of an emergency

          -  other antidiabetics

          -  heart failure or heart failure in the patients history (NYHA I to IV)

          -  history of macular oedema

          -  treatment with thiazolidinediones within 3 months prior to screening

          -  known or suspected history of alcohol and/or drug abuse

          -  treatment with gemfibrozil within 3 months prior to screening
Clinical trial NCT00573157 (phase 2/phase 3, status: terminated)
Conditions: lupus nephritis
ICD codes: B26.83, A51.44, N11.8, N11.9, N12
Drugs: atacicept, mycophenolate mofetil, placebo, corticosteroids
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Reason stopped: 
    the study was terminated due to unanticipated safety issues
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of systemic lupus erythematosus (SLE) satisfying at least 4 out of the 11
             American College of Rheumatology (ACR) criteria (Appendix B)

          -  Renal biopsy performed consistent with active International Society of
             Nephrology/Renal Pathology Society (ISN/PRS) class III or IV lupus nephritis

        Exclusion Criteria:

          -  Estimated glomerular filtration rate (GFR) less than or equal to (<=) 30 milliliter
             per minute (mL/min) per 1.73 square meter (m^2)

          -  Active central nervous system SLE deemed to be severe or progressive and/or associated
             with significant cognitive impairment

          -  Any treatment with MMF, azathioprine, or cyclophosphamide within the last 6 months, or
             known hypersensitivity to MMF or atacicept.

          -  Any prior treatment with abatacept, rituximab, belimumab, or other B cell modulating
             agents.
Clinical trial NCT00502710 (phase 2, status: completed)
Conditions: diabetes mellitus type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: placebo, ro4876904
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CF)CN(C(=O)C1)[C@@]1([H])CN2CCC3=CC(OC)=C(OC)C=C3[C@]2([H])C[C@]1([H])N
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients, 18-75 years of age;

          -  type 2 diabetes diagnosed >= 1 month before screening;

          -  drug-naive, or pretreated with maximum tolerated dose (MTD) of metformin;

          -  BMI 25-45kg/m2.

        Exclusion Criteria:

          -  type 1 diabetes;

          -  any anti-hyperglycemic medication other than metformin, or weight-lowering drug,
             during last 3 months.
Clinical trial NCT01018693 (phase 2, status: completed)
Conditions: seasonal allergic rhinitis
ICD codes: J30.2
Drugs: vak694; alutard avanz sq, vak694 placebo infusion; alutard avanz sq, vak694 placebo infusion; saline
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  History of atopy, defined as a history of seasonal allergic rhinitis for at least 2
             years (in relation to the grass pollen allergy season), and evidence of atopy, defined
             as a positive skin prick test (wheal difference allergen - negative control at least 3
             mm) to grass pollen allergen at screening.

          -  Male or female subjects aged between 18 and 60 years (inclusive)

          -  Female subjects must be of non-childbearing potential

          -  Subjects must weigh at least 50 kg with a body mass index (BMI) within the range of 18
             to 32 kg/m2 (inclusive)

          -  Informed consent

        Exclusion Criteria:

          -  Treatment with intranasal corticosteroids within 28 days prior to the first dose.

          -  History of asthma with treatment with inhaled or systemic corticosteroids within 6
             months of the first dose.

          -  History of COPD.

          -  Any exposure to human monoclonal or polyclonal antibodies.

          -  Any allergy immunotherapy within 3 years prior to screening.

          -  Any prior grass pollen allergy immunotherapy.

          -  FEV1 < 70% of predicted at screening or baseline.

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00191269 (phase 2, status: completed)
Conditions: metastatic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: gemcitabine, gemcitabine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically and/or cytologically confirmed breast cancer

          -  Received prior chemotherapy for metastatic breast cancer with anthracycline and taxane
             regimen

          -  To have at least one measurable region

          -  PS: 0-1

          -  To have adequate organ function (bone marrow, liver and renal function)

        Exclusion Criteria:

          -  To have Interstitial pneumonia or pulmonary fibrosis

          -  To have inflammatory carcinoma

          -  Within 28 days after the latest chemotherapy or radiotherapy, 14 days after the latest
             hormonal/immunotherapy or 7 days after surgery

          -  To have brain metastasis with symptom

          -  To have severe complication (cardiac infarction, infection, drug hyper sensitivity or
             diabetes)
Clinical trial NCT00434122 (phase 2, status: completed)
Conditions: infertility, female
ICD codes: N97.9, N97.0, N97.1, N97.2, N97.8, Z31.81
Drugs: degarelix mid-luteal, 2.5 mg, placebo
SMILES: CC(C)C[C@H](NC(=O)[C@@H](CC1=CC=C(NC(N)=O)C=C1)NC(=O)[C@H](CC1=CC=C(NC(=O)[C@@H]2CC(=O)NC(=O)N2)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria

          -  Signed Informed Consent Form, prior to screening evaluations

          -  In good physical and mental health

          -  Pre-menopausal females between the ages of 18-35 years (both inclusive) at the time of
             randomisation

          -  Regular menstrual cycles of 26-35 days duration (both inclusive), presumed to be
             ovulatory

          -  Body mass index (BMI) between 18 and 29 kg/m2 (both inclusive)

          -  Willing to donate the retrieved oocytes

          -  Willing to use an adequate barrier method of contraception from informed consent to
             Day hCG injection +7 and to use an adequate barrier or hormonal method of
             contraception from Day hCG injection +7 to the end-of-study visit

        Exclusion Criteria

          -  Abnormal karyotype

          -  Any known clinically significant systemic disease (e.g., insulin dependent diabetes)

          -  Any known endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver or
             kidney) which can compromise participation in the study

          -  Diagnosed with polycystic ovarian syndrome or endometriosis stage III/IV

          -  Diagnosed as "poor responder"

          -  History of recurrent miscarriage (defined as three consecutive spontaneous losses
             before weeks 24 of pregnancy)

          -  Pregnancy or lactation

          -  Use of any investigational drug during 3 months prior to start of the current COH
             cycle

          -  Previous participation in the study

          -  Hypersensitivity to any trial product
Clinical trial NCT01375764 (phase 2, status: completed)
Conditions: hyperlipidemia
ICD codes: E78.2, E78.49, E78.5
Drugs: ezetimibe
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female ≥ 18 to ≤ 75 years of age

          -  On a statin or a low dose statin with stable dose for at least 4 weeks

          -  Lipid lowering therapy has been stable prior to enrollment

          -  Fasting triglycerides must be < 400 mg/dL.

          -  Subject not at LDL-C goal

        Exclusion Criteria:

          -  New York Heart Association (NYHA) III or IV heart failure or known left ventricular
             ejection fraction < 30%

          -  Uncontrolled cardiac arrhythmia

          -  Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI),
             coronary artery bypass graft (CABG) or stroke within 3 months prior to randomization

          -  Type 1 diabetes or newly diagnosed type 2 diabetes (HbA1c > 8.5%)

          -  Uncontrolled hypertension
Clinical trial NCT00380354 (phase 2, status: completed)
Conditions: asthma, mild asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40, J45.20, J45.30, J45.21, J45.22, J45.31, J45.32
Drugs: gsk256066
SMILES: COC1=CC=CC(=C1)N=C1C(=CNC2=C1C=C(C=C2C)S(=O)(=O)C1=CC=CC(=C1)C(=O)N(C)C)C(O)=N
Eligibility criteria:

        Inclusion criteria

          -  Documented history of bronchial asthma, first diagnosed at least 6 months prior to the
             screening visit and currently being treated only with intermittent short-acting beta
             -agonist therapy by inhalation.

          -  Pre-bronchodilator FEV1 >75% of predicted at screening.

          -  Non-smoker

          -  Demonstration of a positive reaction to at least one allergen from a battery of
             allergens (including house dust mite, grass pollen and cat hair on skin prick testing
             at screening, or within 12 months of study start.

          -  Have Asthmatic response

          -  Able and willing to give written informed consent to take part in the study.

          -  Available to complete all study measurements.

        Exclusion criteria:

          -  History of cardiovascular disease

          -  Clinically significant abnormalities in safety laboratory analysis at screening
             including any subject who has greater than "trace urine protein levels" following
             urinalysis at screening.

          -  History of hayfever

          -  The subject has tested positive for hepatitis C antibody or hepatitis B surface
             antigen.

          -  The subject has tested positive for HIV antibodies.

          -  The subject has positive drugs of abuse test.

          -  Subjects weighing less than 50kg are to be excluded from participating in the study.

          -  The subject has participated in a study with a new molecular entity during the
             previous 3 months.

          -  History of being unable to tolerate or complete methacholine, and/or allergen
             challenge tests.

          -  There is a risk of non-compliance with study medication or study procedures.

          -  History of blood donation (450 mL) within 2 months of starting the clinical study.

          -  The subject regularly drinks more than 28 units of alcohol in a week if male, or 21
             units per week if female. One unit of alcohol is defined as a medium (125 ml) glass of
             wine, half a pint (250 ml) of beer or one measure (24 ml) of spirits.
Clinical trial NCT00126321 (phase 2, status: unknown status)
Conditions: leukemia, myelocytic, acute
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: cladribine
SMILES: [Mg++].[Cl-].[Cl-]
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with relapsed AML with a remission duration of at least 6 months after first
             complete remission (CR) or of at least 3 months after second (or higher) CR

          -  Age >= 18 years

          -  Life expectancy of at least three months (without consideration of AML and
             complications)

          -  Eastern Cooperative Oncology Group (ECOG) 0-2 (without consideration of AML and
             complications)

          -  Written informed consent

        Exclusion Criteria:

          -  Prior therapy of AML with cladribine

          -  Severe, uncontrolled infection at time of inclusion (enrollment is possible after
             control of infection)

          -  Cardiac insufficiency grade III or IV New York Heart Association (NYHA)

          -  Severe renal insufficiency with a clearance of < 30 ml/min (if not due to AML)

          -  Severe hepatic insufficiency with bilirubin > 3 mg/dl or AST > 200 U/l (if not due to
             AML)

          -  Other severe organ impairment grade III or IV World Health Organization (WHO) (if not
             due to AML or, in the opinion of the investigator, may not interfere with the
             procedures in the study)

          -  HIV infection

          -  Intolerance to study drugs

          -  Pregnant or breast-feeding women

          -  Any other malignant disease which will probably affect the course of AML
Clinical trial NCT00383643 (phase 2, status: completed)
Conditions: sleep initiation and maintenance disorders
ICD codes: Y93.E9, Y93.H9
Drugs: zolpidem tartrate, sodium oxybate, matching placebos
SMILES: CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1, [Na+].OCCCC([O-])=O, COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Written informed consent is obtained.

          2. The patient is an outpatient, man or woman of any ethnic origin, 18-75 years of age
             (inclusive).

          3. Patient reports insomnia for at least six months, and insomnia causes the patient
             distress.

          4. The Investigator determines that the patient meets diagnostic criteria for Chronic
             Insomnia according to International Classification of Sleep Disorders (ICSD) criteria.

          5. Sleep diary based screening shows sleep onset latency >30 minutes, and /or wake after
             sleep onset >30 minutes per night at least 3 nights per week, with combined
             wake-time-in-bed _> 45 minutes.

          6. The patient is in good health as determined by a medical and psychiatric history, and
             physical examination.

          7. Women must be surgically sterile, 2 years post-menopausal, or if of child-bearing
             potential, using a medically accepted method of birth control, and agree to continued
             use of this method for the duration of the study.

          8. The patient is willing and able to comply with study restrictions and to attend
             regularly scheduled clinic visits as specified in this protocol.

        Exclusion Criteria:

          1. Has any clinically significant, uncontrolled medical or psychiatric conditions.
             (treated or untreated)

          2. Has a probable diagnosis of a current sleep disorder other than Chronic Insomnia.

          3. Used any prescription drugs disallowed by the protocol or clinically significant use
             of over-the counter(OTC) drugs within 14 days before the screening visit.

          4. Has a history of alcohol, narcotic, or any other abuse as defined by the DSM-V.

          5. Has a clinically significant deviation from normal in the physical examination.

          6. Is a pregnant or lactating woman. (Any woman becoming pregnant during the study will
             be withdrawn from the study.)

          7. Has any disorder that may interfere with drug absorption, distribution, metabolism, or
             excretion (including gastrointestinal surgery and succinic semialdehyde dehydrogenase
             deficiency)

          8. Has a known clinically significant drug sensitivity to sodium oxybate or sedative
             hypnotics.
Clinical trial NCT00250926 (phase 2, status: completed)
Conditions: waldenstrom's macroglobulinemia
ICD codes: C88.0
Drugs: bortezomib, dexamethasone, rituximab
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  Clinicopathological diagnosis of Waldenstrom's macroglobulinemia (WM)

          -  No previous therapy for WM

          -  Measurable disease, defined as presence of immunoglobulin M (IgM) paraprotein with a
             minimum IgM level of greater than or equal to 2 times the upper limit of each
             institution's normal value

          -  CD20 positive disease based on any previous bone marrow immuno-histochemistry or flow
             cytometric analysis performed up to 3 months prior to enrollment

          -  Karnofsky performance status > 60

          -  Life expectancy > 3 months

          -  AST (SGOT) < 3 x ULN

          -  ALT (SGPT) < 3 x ULN

          -  Total bilirubin < 2 x ULN

          -  Calculated or measured creatinine clearance > 30mL/minute

          -  Serum sodium > 130 mmol/L

          -  Female subject is either post-menopausal or surgically sterilized or willing to use an
             acceptable method of birth control

          -  Male subject agrees to use an acceptable method for contraception for the duration of
             the study

        Exclusion Criteria:

          -  Previous therapy for Waldenstrom's macroglobulinemia

          -  Myocardial infarction within 6 months prior to enrollment or has New York Hospital
             Association Class III or IV heart failure, uncontrolled angina, severe uncontrolled
             ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active
             conduction system abnormalities.

          -  Hypersensitivity to dexamethasone, boron or mannitol

          -  Pregnant or breast-feeding women

          -  Serious medical or psychiatric illness likely to interfere with participation in this
             clinical study